Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

Mucosal Immunology

Volumn 7, Issue 1, 2014, Pages 46-56

  Moog, C ^a   Dereuddre Bosquet, N ^b,c   Teillaud, J L ^d   Biedma, M E ^a   Holl, V ^a,k   Van Ham, G ^e   Heyndrickx, L ^e   Van Dorsselaer, A ^f   Katinger, D ^g   Vcelar, B ^g   Zolla Pazner, S ^h   Mangeot, I ^b,c   Kelly, C ⁱ   Shattock, R J ^j   Le Grand, R ^b,c  

^a INSERM   (France)

^b CEA   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f INSTITUT DE RECHERCHES SUBATOMIQUES   (France)

^g Polymun Scientific GmbH   (Austria)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j IMPERIAL COLLEGE LONDON   (United Kingdom)

^k Hematology and Flow Department   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; NEUTRALIZING ANTIBODY; NONNEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FEMALE; HIV ANTIBODIES; IMMUNOGLOBULIN FC FRAGMENTS; MACACA FASCICULARIS; MACROPHAGES; NEUTRALIZATION TESTS; PROTEIN BINDING; RECEPTORS, IGG; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINA; VIRUS REPLICATION;

EID: 84890899378     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2013.23     Document Type: Article

References (48)

1. Florese, R.H. et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 177, 4028-4036 (2006).
2. Mascola,J.R., Frankel, S.S.&Broliden, K.HIV-1entryat themucosal surface: role of antibodies in protection. AIDS 14 (Suppl 3), S167-S174 (2000).
3. Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
4. Hessell, A.J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009).
5. Ruprecht, R.M. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol. 525, 559-566. xiv (2009).
6. Burton, D.R. et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 108, 11181-11186 (2011).
7. Gomez-Roman, V.R. et al. Vaccine-elicited antibodies mediate antibodydependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174, 2185-2189 (2005).
8. Forthal, D.N. & Moog, C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4, 388-393 (2009).
9. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
10. Haynes, B.F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
11. Moore, P.L. et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80, 2515-2528 (2006).
12. Hessell, A.J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951-954 (2009).
13. Peressin, M. et al. HIV-1 replication in Langerhans and interstitial dendritic cells is inhibited by neutralizing and Fc-mediated inhibitory antibodies. J. Virol. 85, 1077-1085 (2011).
14. Barouch, D.H. et al. Vaccine protection against acquisition of neutralization- resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
15. Baum, L.L. Role of humoral immunity in host defense against HIV. Curr. HIV/AIDS Rep. 7, 11-18 (2010).
16. Holl, V. et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80, 6177-6181 (2006).
17. Holl, V. et al. Involvement of Fcgamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173, 6274-6283 (2004).
18. Holl, V. et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107, 4466-4474 (2006).
19. Hezareh, M., Hessell, A.J., Jensen, R.C., van de Winkel, J.G. & Parren, P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75, 12161-12168 (2001).
20. Smalls-Mantey, A. et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86, 8672-8680 (2012).
21. Burrer, R., Haessig-Einius, S., Aubertin, A.M. & Moog, C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 333, 102-113 (2005).
22. Kent, S.J., Stent, G., Sonza, S., Hunter, S.D. & Crowe, S.M. HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. Clin. Exp. Immunol. 95, 450-454 (1994).
23. Perez, L.G., Costa, M.R., Todd, C.A., Haynes, B.F. & Montefiori, D.C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J. Virol. 83, 7397-7410 (2009).
24. Maillard, P. et al. Fcgamma receptor-like activity of hepatitis C virus core protein. J Biol Chem 279, 2430-2437 (2004).
25. Siberil, S. et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin. Immunol. 118, 170-179 (2006).
26. Chou, T.C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
27. Verrier, B. et al. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol. 21, 653-658 (2002).
28. Xu, J.Y., Gorny,M.K., Palker, T., Karwowska, S. & Zolla-Pazner, S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65, 4832-4838 (1991).
29. Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359-369 (1994).
30. Harouse, J.M., Gettie, A., Tan, R.C., Blanchard, J. & Cheng-Mayer, C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816-819 (1999).
31. Harouse, J.M. et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J. Virol. 75, 1990-1995 (2001).
32. Warncke, M. et al. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J. Immunol. 188, 4405-4411 (2012).
33. Moldt, B. et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J. Virol. 85, 10572-10581 (2011).
34. Moldt, B. et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189-6196 (2012).
35. Dereuddre-Bosquet, N. et al. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. PLoS Pathog. 8, e1003071 (2012).
36. Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109, 18921-18925 (2012).
37. Stoiber, H., Speth, C. & Dierich, M.P. Role of complement in the control of HIV dynamics and pathogenesis. Vaccine 21 (Suppl 2), S77-S82 (2003).
38. Huber, M. et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J. Virol. 82, 3834-3842 (2008).
39. Bialuk, I. et al. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine 30, 78-94 (2011).
40. Parren, P.W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
41. Ferrantelli, F. et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189, 2167-2173 (2004).
42. Ferrantelli, F. et al. Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 358, 69-78 (2007).
43. Li, Z., Palaniyandi, S., Zeng, R., Tuo, W., Roopenian, D.C. & Zhu, X. Transfer of IgG in the female genital tract byMHCclass I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl. Acad. Sci. USA 108, 4388-4393 (2011).
44. Kunert, R., Steinfellner, W., Purtscher, M., Assadian, A. & Katinger, H. Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnol. Bioeng. 67, 97-103 (2000).
45. Nyambi, P.N., Burda, S., Bastiani, L. & Williams, C. A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1. J. Immunol. Methods 253, 253-262 (2001).
46. Heyndrickx, L. et al. International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One 7, e36438 (2012).
47. Bourry, O. et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS 23, 447-454 (2009).
48. Aarnink, A. et al. Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque. Immunogenetics 63, 267-274 (2011).